TY - JOUR
T1 - Direct oral anticoagulant use
T2 - A practical guide to common clinical challenges
AU - Chen, Ashley
AU - Stecker, Eric
AU - Warden, Bruce A.
N1 - Publisher Copyright:
© 2020 The Authors.
PY - 2020/7/7
Y1 - 2020/7/7
N2 - Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings. With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios. Topics addressed include (1) appropriate indications; (2) use in patients with specific comorbidities; (3) monitoring parameters; (4) transitioning between anticoagulant regimens; (5) major drug interactions; and (6) cost considerations.
AB - Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings. With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios. Topics addressed include (1) appropriate indications; (2) use in patients with specific comorbidities; (3) monitoring parameters; (4) transitioning between anticoagulant regimens; (5) major drug interactions; and (6) cost considerations.
KW - Anticoagulation
KW - Oral direct thrombin inhibitor
KW - Oral factor Xa inhibitors
KW - Pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=85088211310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088211310&partnerID=8YFLogxK
U2 - 10.1161/JAHA.120.017559
DO - 10.1161/JAHA.120.017559
M3 - Article
C2 - 32538234
AN - SCOPUS:85088211310
SN - 2047-9980
VL - 9
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 13
M1 - e017559
ER -